Candel Therapeutics Prostate Cancer Therapy Shows Promise

Exec Edge
2024-12-12

By Karen Roman

Candel Therapeutics, Inc. (Nasdaq: CADL) said Phase 3 of its prostate cancer candidate CAN-2409 showed an upgrade in disease-free survival in intermediate-to-high-risk patients.

“We look forward to working with the FDA, as a next step, to seek approval to bring CAN-2409 to patients in the U.S., and advance our broad viral immunotherapy pipeline across other large oncology indications of high unmet need,” said Paul Peter Tak, Candel’s President and CEO.

Contact:

Exec Edge

Editor@Executives-edge.com

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10